A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Active, not recruiting · Phase 3 · NCT06339008
Conditions: Perennial Allergic Rhinitis (PAR)
At a glance
- Research payments reported, 2025
- $3.2M
- U.S. investigators named
- 27
- Sites paid
- 18
- Planned or actual enrollment
- 450
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3650150 (drug), Placebo (drug), Standard therapy for INCS (drug)
- Dates
- Started 2024-04-26; completion 2028-10
- Results posted
- Not yet
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.2M in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Warner W. Carr, MD Allergy & Immunology · Laguna Niguel, CA
- Bob Geng, M.D. Allergy & Immunology · San Diego, CA
- Soheil P. Hekmat, MD Internal Medicine · Inglewood, CA
- Steven F. Weinstein, MD Allergy & Immunology · Huntington Beach, CA
- Luke M. Webb, MD Internal Medicine · Colorado Springs, CO
- Ronald H. Saff, MD Allergy & Immunology · Tallahassee, FL
- Anju Peters, M.D. Allergy & Immunology · Chicago, IL
- William A. Greisner, MD Allergy & Immunology · Lexington, KY
- Jeffrey G. Leflein, MD Allergy & Immunology · Ypsilanti, MI
- Gary D. Berman, M.D. Allergy & Immunology · Minneapolis, MN
- Christine B. Franzese, M.D. ENT (Otolaryngology) · Columbia, MO
- William L. Johnson, MD Pediatrics · Saint Louis, MO
- David M. Cypcar, MD Allergy & Immunology · Asheville, NC
- Linda B. Ford, M.D. Allergy & Immunology · Bellevue, NE
- Patrick V. Perin, MD Allergy & Immunology · Teaneck, NJ
- Peter A. Ricketti, D.O. Allergy & Immunology · Trenton, NJ
- Ellen R. Sher, M.D. Allergy & Immunology · Ocean, NJ
- Mark E. Weinstein, M.D. Allergy & Immunology · Belleville, NJ
- David I. Bernstein, M.D. Allergy & Immunology · Cincinnati, OH
- Rachana Shah, M.D Pediatric Hematology & Oncology · Cincinnati, OH
- Subramaniam Seetharaman, MD Family Medicine · Milwaukie, OR
- Michael J. Palumbo, M.D. Allergy & Immunology · Pittsburgh, PA
- Christopher H. Smith, M.D. Cardiology · Greenville, SC
- Niran J. Amar, M.D. Allergy & Immunology · Waco, TX
- William R. Lumry, M.D. Specialist · Dallas, TX
- Dale E. Mohar, MD Allergy & Immunology · Kerrville, TX
- Gary C. Steven, M.D. Allergy & Immunology · Greenfield, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Crn Clinical Research Network $813,768
- Allergy & Clinical Immunology $457,264
- Elligo Health Research Inc $393,719
- Dale E Mohar, MD $382,202
- Respiratory Medicine Research $321,216
- Midwest Clinical Research LLC $239,517
- Empirican Prn Inc $107,723
- Asthma and Allergy Center of Chicago $106,772
- Allergy PArtners of Nj $84,070
- Mercy Health - Lourdes Hospital LLC $83,723
- Bernstein Clinical Research Center LLC $46,363
- Allergy PArtners PA $42,052
- Northwestern University $40,640
- Finger Lakes Medical Research PLLC $32,889
- Steven F Weinstein MD A Profes $32,117
- University of Missouri Health Care, MO $19,430
- Meeting Protocol Worldwide LP $8,522
- Allergy Asthma Research Institute $3,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.